International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(23), С. 12929 - 12929
Опубликована: Дек. 1, 2024
Clear
cell
renal
carcinoma
(ccRCC)
is
the
most
common
kidney
malignancy,
with
a
poor
prognosis
for
advanced-stage
patients.
Identifying
key
biomarkers
involved
in
tumor
progression
crucial
improving
treatment
outcomes.
In
this
study,
we
employed
an
integrated
approach
combining
single-cell
RNA
sequencing
(scRNA-seq)
and
bulk
(bulk
RNA-seq)
to
identify
associated
ccRCC
prognosis.
Single-cell
transcriptomic
data
were
obtained
from
publicly
available
datasets,
genes
related
screened
using
Monocle2.
Bulk
RNA-seq
retrieved
The
Cancer
Genome
Atlas
(TCGA)
scRNA-seq
explore
heterogeneity.
We
identified
3
beta-hydroxy
steroid
dehydrogenase
type
7
(HSD3B7)
as
candidate
biomarker
ccRCC,
overall
survival,
disease-specific
progression-free
interval.
Elevated
HSD3B7
expression
correlated
aggressive
clinical
features
such
advanced
TNM
stages,
histologic
grades,
metastasis.
Functional
studies
demonstrated
that
promotes
proliferation,
migration,
invasion
vitro,
while
its
silencing
significantly
inhibits
growth
vivo.
Our
findings
reveal
novel
providing
insights
into
role
potential
target
therapy.
This
study
highlights
value
of
integrating
uncover
regulators
biology
lays
foundation
developing
personalized
therapeutic
strategies
Journal of Nuclear Medicine,
Год журнала:
2025,
Номер
unknown, С. jnumed.124.268835 - jnumed.124.268835
Опубликована: Фев. 27, 2025
CD70
is
an
emerging
biomarker
for
both
solid
tumors
and
hematologic
malignancies,
highlighting
the
urgent
need
a
molecular
imaging
tracer
capable
of
visualizing
with
favorable
pharmacokinetics.
Methods:
ABDB6
was
prepared
by
fusing
albumin-binding
domain
ABD035
CD70-targeting
single-domain
antibody
RCCB6,
which
we
previously
reported.
The
resulting
then
conjugated
to
bifunctional
chelator
p-SCN-NOTA
labeled
64Cu
produce
[64Cu]Cu-NOTA-ABDB6.
Flow
cytometry
used
screen
6
lymphoma
cell
lines
varying
expression
levels.
Cell
uptake
in
vivo
immuno-PET
studies
were
conducted
fully
evaluate
pharmacokinetic
properties
tumor-targeting
efficacy
An
blocking
study
performed
validate
targeting
specificity
[64Cu]Cu-NOTA-ABDB6,
followed
immunohistochemistry
fluorescent
immunostaining
correlate
expression.
Results:
labeling
achieved
high
radiochemical
yield
specific
activity.
Significant
observed
5
(TMD8,
HBL1,
OCI-LY10,
LCL-EBV,
type
III
latency
Burkitt
[BL]
cells)
but
not
I
BL
cells,
served
as
negative
control.
[64Cu]Cu-NOTA-ABDB6
exhibited
good
affinity
protein
at
nanomolar
level
(inhibitory
concentration
50%,
91.57
nM)
binding
human
CD70.
Immuno-PET
demonstrated
excellent
tumor
retention
various
CD70-positive
models
BL,
LCL-EBV),
highest
values
recorded
24.67
±
1.36,
18.02
4.29,
14.68
1.20
percentage
injected
dose
per
gram
tissue
(%ID/g)
48
h
after
injection,
respectively.
These
significantly
higher
than
that
CD70-negative
tumor,
had
3.59
0.28
%ID/g
same
scanning
time
point
(P
<
0.05).
In
TMD8
group,
5.99
lower
control
group
0.01).
Both
biodistribution
histology
results
corroborated
these
findings.
Conclusion:
effectively
visualized
levels
different
models.
Its
clinical
potential
may
provide
insights
into
patients.
Molecular Pharmaceutics,
Год журнала:
2025,
Номер
unknown
Опубликована: Май 30, 2025
Pancreatic
adenocarcinoma
(PAAD)
is
an
extremely
lethal
cancer,
making
early
detection
and
precise
staging
essential
for
extending
survival.
Upregulation
of
5T4
mRNA
was
detected
in
bioinformatics
analysis
using
data
from
the
Cancer
Genome
Atlas
Genotype-Tissue
Expression.
In
current
work,
we
confirmed
overexpression
protein
tumor
samples
PAAD
compared
with
corresponding
paraneoplastic
tissue.
To
visualize
via
positron
emission
tomography
(PET)
noninvasively,
successfully
developed
[18F]AlF-RESCA-H006
based
on
a
single-domain
antibody
fragment.
The
radiotracer
demonstrated
high
binding
affinity
toward
antigens
vitro
remained
stable
final
formulation
up
to
4
h
storage
at
room
temperature.
two
preclinical
mouse
models
pancreatic
clearly
identified
sites,
showing
radioactivity
accumulation
2.43
±
0.46%
ID/g
Balb/C
mice
BxPC-3
xenografts
2.88
1.02%
NCG
PANC-1
xenografts.
Taken
together,
promising
PET
tracer
detecting
antigen
alteration
PAAD.
Further
investigations
are
required
assess
its
defluorination
level
higher
species
permeability
through
dense
extracellular
matrix
cancer.
Immunotherapy Advances,
Год журнала:
2024,
Номер
4(1)
Опубликована: Янв. 1, 2024
The
evolving
landscape
of
cancer
immunotherapy
has
revolutionized
treatment.
However,
the
dynamic
tumor
microenvironment
led
to
variable
clinical
outcomes,
indicating
a
need
for
predictive
biomarkers.
Noninvasive
nuclear
imaging,
using
radiolabeled
modalities,
aided
in
patient
selection
and
monitoring
their
treatment
response.
This
approach
holds
promise
improving
diagnostic
accuracy,
providing
more
personalized
regimen,
enhancing
Nanobodies
or
single-domain
antibodies,
derived
from
camelid
heavy-chain
allow
early
timepoint
detection
targets
with
high
target-to-background
ratios.
To
date,
plethora
nanobodies
have
been
developed
imaging
tumor-specific
antigens,
immune
checkpoints,
cells,
both
at
preclinical
level.
review
comprehensively
outlines
recent
advancements
nanobody-based
on
levels.
Additionally,
impact
expected
future
use
radiopharmaceuticals
supporting
diagnosis
follow-up
are
discussed.
